HLA Typing Market in United States, United Kingdom– Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)

HLA Typing Market – Report Overview

Pacific Business Consulting’s “HLA Typing Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)” report offers a comprehensive understanding of HLA Typing market, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Ten Major Markets (10MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, China, Australia, and India.

In 2022, the HLA Typing market exceeded a valuation of US$ 1.2 Billion, and it is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) surpassing 5.0% from 2023 to 2030. The market is expected to potentially surpass US$ 2.0 Billion by 2030.

The increasing demand for organ transplantation, coupled with the widespread use of human leukocyte antigen (HLA) testing in pharmacogenetics, is anticipated to be a key growth driver for the market. HLA matching is crucial for determining the compatibility of tissue transplantation, reducing the likelihood of complications post-transplantation.

The adoption of HLA testing in various applications, such as personalized cancer immunotherapy, contributes to the test’s expanded scope and increased demand. For instance, NEC Oncolmmunity AS, in collaboration with Ultimovacs ASA, published research in February 2022 detailing a method to test new HLA alleles and characterize tumors’ HLA using next-generation sequencing (NGS). This breakthrough in personalized immunotherapy is expected to fill gaps in HLA libraries globally and enhance accuracy for organ transplants and vaccine design.

The diagnostic techniques for HLA typing have evolved from serology-based to genome-based procedures, incorporating PCR-based genome sequencing integrated with microfluidics, biomedical instrumentation, and robotics. These technological advancements have led to higher sample throughput, increased sensitivity, early detection of incompatibility, and improved procedural efficacy compared to serological techniques.

Market players have commercialized PCR and NGS-based HLA typing reagents, detecting genetic modifications and determining precise HLA alleles. Efforts to boost the healthcare industry and rising disposable incomes globally have further contributed to the industry’s growth.

Factors contributing to the growth of the global HLA typing market include the rise in organ transplants, increasing prevalence of chronic and infectious diseases, advancements in molecular assays for HLA typing, availability of funding for HLA typing research, and growing public awareness regarding organ donations.

Molecular assays represent the most significant technology segment in the HLA typing market for transplants, offering advantages such as high procedural efficacy, real-time sample analysis, low turnaround time, and the ability to analyze multiple samples.

Despite the prominence of molecular assays in HLA typing, their high costs remain a significant challenge. Additionally, the gap between the demand for organs for transplantation and the availability of organ donations presents a substantial obstacle for the HLA typing market.

Leading players in the HLA Typing segment, including Immucor Inc., Histogenetics LLC, TBG Diagnostics Ltd., CareDX Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Hologic Inc., Bio Reference Laboratories, Abbott Laboratories Ltd., Omixon Inc., are expected to play a crucial role in shaping the future landscape of HLA Typing technologies through ongoing innovation.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the HLA Typing market. It also delves into the analysis of present and prospective market competition within the global HLA Typing market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the HLA Typing market across the 10MM (Ten Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 10MM HLA Typing market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

HLA Typing Market – Report Overview

Pacific Business Consulting’s “HLA Typing Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)” report offers a comprehensive understanding of HLA Typing market, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Ten Major Markets (10MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, China, Australia, and India.

In 2022, the HLA Typing market exceeded a valuation of US$ 1.2 Billion, and it is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) surpassing 5.0% from 2023 to 2030. The market is expected to potentially surpass US$ 2.0 Billion by 2030.

The increasing demand for organ transplantation, coupled with the widespread use of human leukocyte antigen (HLA) testing in pharmacogenetics, is anticipated to be a key growth driver for the market. HLA matching is crucial for determining the compatibility of tissue transplantation, reducing the likelihood of complications post-transplantation.

The adoption of HLA testing in various applications, such as personalized cancer immunotherapy, contributes to the test’s expanded scope and increased demand. For instance, NEC Oncolmmunity AS, in collaboration with Ultimovacs ASA, published research in February 2022 detailing a method to test new HLA alleles and characterize tumors’ HLA using next-generation sequencing (NGS). This breakthrough in personalized immunotherapy is expected to fill gaps in HLA libraries globally and enhance accuracy for organ transplants and vaccine design.

The diagnostic techniques for HLA typing have evolved from serology-based to genome-based procedures, incorporating PCR-based genome sequencing integrated with microfluidics, biomedical instrumentation, and robotics. These technological advancements have led to higher sample throughput, increased sensitivity, early detection of incompatibility, and improved procedural efficacy compared to serological techniques.

Market players have commercialized PCR and NGS-based HLA typing reagents, detecting genetic modifications and determining precise HLA alleles. Efforts to boost the healthcare industry and rising disposable incomes globally have further contributed to the industry’s growth.

Factors contributing to the growth of the global HLA typing market include the rise in organ transplants, increasing prevalence of chronic and infectious diseases, advancements in molecular assays for HLA typing, availability of funding for HLA typing research, and growing public awareness regarding organ donations.

Molecular assays represent the most significant technology segment in the HLA typing market for transplants, offering advantages such as high procedural efficacy, real-time sample analysis, low turnaround time, and the ability to analyze multiple samples.

Despite the prominence of molecular assays in HLA typing, their high costs remain a significant challenge. Additionally, the gap between the demand for organs for transplantation and the availability of organ donations presents a substantial obstacle for the HLA typing market.

Leading players in the HLA Typing segment, including Immucor Inc., Histogenetics LLC, TBG Diagnostics Ltd., CareDX Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Hologic Inc., Bio Reference Laboratories, Abbott Laboratories Ltd., Omixon Inc., are expected to play a crucial role in shaping the future landscape of HLA Typing technologies through ongoing innovation.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the HLA Typing market. It also delves into the analysis of present and prospective market competition within the global HLA Typing market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the HLA Typing market across the 10MM (Ten Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 10MM HLA Typing market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.